Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  Cytoskeletal Signaling >  HSP e.g. HSP90 activators >  Elesclomol

Elesclomol

Basic information Safety Supplier Related

Elesclomol Basic information

Product Name:
Elesclomol
Synonyms:
  • elescloMol, N'1,N'3-diMethyl-N'1,N'3-di(phenylcarbonothioyl)Malonohydrazide
  • elesclomol
  • 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid
  • STA-4783
  • ElescloMol (STA-4783)
  • N1',N3'-dimethyl-N1',N3'-di(phenylcarbonothioyl)malonohydrazide
  • STA-4783;STA4783
  • CS-482
CAS:
488832-69-5
MF:
C19H20N4O2S2
MW:
400.52
Product Categories:
  • Inhibitors
  • APIs
Mol File:
488832-69-5.mol
More
Less

Elesclomol Chemical Properties

Density 
1.313
storage temp. 
Store at -20°C
solubility 
insoluble in H2O; ≥20.15 mg/mL in DMSO; ≥5.68 mg/mL in EtOH with gentle warming and ultrasonic
form 
solid
pka
7.99±0.70(Predicted)
color 
Light yellow to yellow
InChI
InChI=1S/C19H20N4O2S2/c1-22(18(26)14-9-5-3-6-10-14)20-16(24)13-17(25)21-23(2)19(27)15-11-7-4-8-12-15/h3-12H,13H2,1-2H3,(H,20,24)(H,21,25)
InChIKey
BKJIXTWSNXCKJH-UHFFFAOYSA-N
SMILES
C1=CC(C(=S)N(C)NC(=O)CC(=O)NN(C)C(=S)C2C=CC=CC=2)=CC=C1
More
Less

Elesclomol Usage And Synthesis

Uses

Elesclomol (STA-4783) is a potent copper ionophore and promotes copper-dependent cell death (cuproptosis). Elesclomol specifically binds ferredoxin 1 (FDX1) α2/α3 helices and β5 strand. Elesclomol inhibits FDX1-mediated Fe-S cluster biosynthesis. Elesclomol is an oxidative stress inducer that induces cancer cell apoptosis. Elesclomol is a reactive oxygen species (ROS) inducer. Elesclomol can be used for Menkes and associated disorders of hereditary copper deficiency research[1][2][3][4].

Definition

ChEBI: A carbohydrazide obtained by formal condensation of the carboxy groups of malonic acid with the hydrino groups of two molar equivalents of N-methylbenzenecarbothiohydrazide

Biological Activity

elesclomol (also known as sta-4783), originally identified in a cell-based phenotypic screen for proapoptotic activity, is a novel small-molecule that potently induces apoptosis of cancer cells through the rapid generation of reactive oxygen species (ros) and the induction of unmanageable levels of oxidative stress. elesclomol exhibits autitumor activity against a broad spectrum of types of cancer cell in human tumor xengograft models due to its excessive ros production and elevated levels of oxidative stress leading to the death of cancer cells. elesclomol is currently being studies as a novel cancer therapeutic, in which it has demonstrated ability to prolong progression-free survival in study subjects.ronald k. blackman, kahlin cheung-ong, marinella gebbia, david a. proia, suqin he, jane kepros, aurelie jonneaux, philippe marchetti, jerome kluza, patricia e. rao, yumiko wada, guri giaever, corey nislow. mitochondrial electron transport is the cellular target of the oncology drug elesclomol. plos one 2012; 7(1): e29798jessica r. kirshner, suqin he, vishwasenani balasubramanyam, jane kepros, chin-yu yang, mei zhang, zhenjian du, james barsoum, and john bertin. elesclomol induces cancer cell apoptosis through oxidative stress. mol cancer ther 2008; 7:2319-2327

in vivo

Elesclomol (10 mg/kg; subcutaneous injection; every three days from post-natal day 5 to 26 and once weekly until post-natal day 54) treatment ameliorates severe cardiac pathology with a partial reduction in hypertrophy. Cardiac [Cu] increased with Elesclomol treatment from a vehicle knockout level of 34 to 55%[4].
Elesclomol escorted copper to the mitochondria and increased cytochrome c oxidase levels in the brain. Elesclomol prevents detrimental neurodegenerative changes and improved the survival of the mottled-brindled mouse[4].

Animal Model:Cardiac Ctr1 knockout mice[4]
Dosage:10 mg/kg
Administration:Subcutaneous injection; every three days from post-natal day 5 to 26 and once weekly until post-natal day 54
Result:Ameliorated severe cardiac pathology with a partial reduction in hypertrophy.

target

HSP70

References

[1] Peter Tsvetkov, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022 Mar 18;375(6586):1254-1261. DOI:10.1126/science.abf0529
[2] Peter Tsvetkov, et al. Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol. 2019 Jul;15(7):681-689. DOI:10.1038/s41589-019-0291-9
[3] Kirshner JR, et al. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther. 2008 Aug;7(8):2319-27. DOI:10.1158/1535-7163.MCT-08-0298
[4] Liam M Guthrie, et al. Elesclomol alleviates Menkes pathology and mortality by escorting Cu to cuproenzymes in mice. Science. 2020 May 8;368(6491):620-625. DOI:10.1126/science.aaz8899
[5] Bair JS, et al. Chemistry and biology of deoxynyboquinone, a potent inducer of cancer cell death. J Am Chem Soc. 2010 Apr 21;132(15):5469-7 DOI:10.1021/ja100610m

ElesclomolSupplier

Shanghai Yuanding Chem. Sci. & Tech. Co., Ltd. Gold
Tel
21-57721279
Email
sales@shydchem.com.cn
Wuhan Shanhai Zhihe Biotechnology Co., Ltd. Gold
Tel
17771424646
Email
shoubull@126.com
Suzhou Chirui Zhihe Biotechnology Co., Ltd. Gold
Tel
0512-13626191578 13626191578
Email
1286165382@qq.com
Shanghai Fine Biotech Co.,Ltd Gold
Tel
18221172427
Email
sale@fine-biotech.com
Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com